Duke University

The University of Alabama

University of California

The United States of America, As Represented by the Secretary, Department of Health and Human Services

The UAB Research Foundation (The University of Alabama at Birmingham)

Los Alamos National Security, LLC

Triad National Security, LLC

The Administrators of the Tulane Educational Fund

Julie Decker

Beatrice H Hahn

George M Shaw

Barton F Haynes

Hua-Xin Liao

Bette T Korber

Feng Gao

Ying Ying Li

Denise Kothe

Peter D Kwong

James E Robinson

Frederic Bibollet-Ruche

Denise L Monti

The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of HIV primary isolates and/or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and/or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens.

Consensus/ancestral immunogens

The invention relates to HIV-1 envelope polypeptides comprising the consensus envelope of SEQ ID NO: 35, compositions comprising these envelopes and methods for using same.

Modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins capable of inducing broadly reactive T- and B-cell responses

Methods and compositions are provided for the use of an envelope polypeptide or a functional variant thereof from a lentivirus that is not HIV-1 as a molecular scaffold for HIV-1 epitopes. The HIV-1 epitopes can be recognized by HIV-1 binding antibodies, HIV-1 neutralizing antibodies and/or CD4-induced antibodies. Thus, methods are provided for detecting HIV-1 binding antibodies in a subject infected with HTV-1. Further provided are methods to determine an epitope for an HIV-1 binding antibody; methods to assay for an HIV-1 binding antibody; methods to identify a soluble CD4 mimic; methods to neutralize an non-HIV-1 virus; diagnostic assays to monitor HIV disease in a subject or to monitor the subject's response to immunization by a HIV vaccine; and methods to alter the neutralization potential of an HIV-1 derived CD4-induced antibody. Chimeric polypeptides, chimeric polynucleotides, kits, cells and viruses are also provided.

Molecular scaffolds for HIV-1 epitopes

Nucleic acids encoding modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins

Growing community of inventors

Alabaster, AL, United States of America

Julie Decker